SCHEMBL10046212

SCHEMBL10046212

CCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(=O)O)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GLP1R P43220 8/20 0.66
NOD1 Q9Y239 9/20 0.58
FOLH1 Q04609 1/20 0.45
PLA2G10 O15496 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19879791 1.00 GLP1R (0.66) GLP1RNOD1FOLH1PLA2G10
SCHEMBL13034811 1.00 GLP1R (0.66) GLP1RNOD1FOLH1PLA2G10
SCHEMBL12981754 1.00 GLP1R (0.66) GLP1RNOD1FOLH1PLA2G10
SCHEMBL15896588 1.00 GLP1R (0.66) GLP1RNOD1FOLH1PLA2G10
SCHEMBL24983192 0.99 GLP1R (0.68) GLP1RNOD1FOLH1PLA2G10
SCHEMBL21754511 0.94 GLP1R (0.69) GLP1RNOD1
SCHEMBL16182576 0.94 GLP1R (0.72) GLP1RNOD1
SCHEMBL17244046 0.94 GLP1R (0.72) GLP1RNOD1
SCHEMBL16182577 0.94 GLP1R (0.72) GLP1RNOD1
SCHEMBL10315877 0.94 GLP1R (0.72) GLP1RNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9181305-B2 Exendin-4 peptide analogues SANOFI (FR) 2015-11-10 US disclosed
US-20120035099-A1 FGF21 ANALOGUES AND DERIVATIVES NOVO NORDISK A/S (DK) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035099-A1 FGF21 ANALOGUES AND DERIVATIVES FGF1, FGFR1, FGF2 GLP1R 11/4885NOD1 1732/4885FOLH1 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.